ORIC Pharma - Wutah bathi EPS kuartalan ORIC

High costs for early-stage oncology drug trials are creating financial pressure, as evidenced by the quarterly EPS gap on the GURU.Markets chart, where 17.20 reflects the latest metric value. The stability of ORIC Pharmaceuticals (ORIC) relies on regulatory approvals and investment inflows. Future revenue is based on the commercialization of agents designed to overcome drug resistance in cancer.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan oricpharma.com (ORIC): kanggo periode 04.07.2022 - 10.11.2026

Rincian analitis perusahaan ORIC Pharmaceuticals

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham ORIC Pharmaceuticals, Inc.|ORIC - Rega prakiraan analis

- rincian nilai pasar emiten:

Kapitalisasi pasar ORIC Pharma|ORIC - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham ORIC Pharmaceuticals|ORIC - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku oricpharma.com|ORIC - Aset Neraca Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal ORIC Pharmaceuticals|ORIC - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas ORIC Pharmaceuticals|ORIC - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku ORIC Pharma|ORIC - Utang jangka dawa|Utang jangka cendhak perusahaan ORIC Pharmaceuticals|Indikator likuiditas cepet oricpharma.com

- rincian bathi lan kelipatan pasar:

ORIC - Bathi pungkasan|Bathi mangsa ngarep ORIC Pharmaceuticals|ORIC - Rasio rega pasar marang bathi resik|Pangali Forward P/E ORIC Pharma|ORIC - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA ORIC Pharma|ORIC - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan ORIC Pharmaceuticals|ORIC - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan oricpharma.com|ORIC - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ORIC Pharmaceuticals

Pambiji fundamental perusahaan:ORIC Pharmaceuticals, Inc. - ORIC

ORIC Pharmaceuticals is investing in R&D without commercial products, leading to a planned depletion of reserves. This metric measures the percentage change in earnings per share between quarters, reflecting the efficiency of capital management. The indicator allows for an assessment of reporting transparency and the cash burn rate. This analysis helps determine the risk of overpaying for future successes. The history of quarterly EPS growth visualizes these financial fluctuations.

Analisis perusahaan pesaing